Stay updated on Nivolumab vs Ipilimumab in Melanoma Recurrence Prevention Clinical Trial
Sign up to get notified when there's something new on the Nivolumab vs Ipilimumab in Melanoma Recurrence Prevention Clinical Trial page.

Latest updates to the Nivolumab vs Ipilimumab in Melanoma Recurrence Prevention Clinical Trial page
- Check2 days agoChange DetectedThe study page now lists melanoma among related topics from MedlinePlus Genetics, and the site revision label advances from v3.8.0 to v3.8.1.SummaryDifference0.1%

- Check9 days agoChange DetectedThe ClinicalTrials.gov record for the completed CheckMate 238 melanoma study is now displayed, including study design, participant criteria, outcomes, and locations. It also provides related publications and study documents.SummaryDifference100%

- Check16 days agoChange DetectedThe site footer revision changes from v3.7.2 to v3.8.0, while the study page continues to show a 403 Forbidden error.SummaryDifference0.2%

- Check30 days agoChange DetectedAn NIH-wide banner about terminology changes during a transition appeared, and the site revision advanced from v3.7.1 to v3.7.2.SummaryDifference1%

- Check44 days agoChange DetectedThe footer revision identifier changed from v3.7.0 to v3.7.1 on the 403 error page.SummaryDifference0.2%

- Check58 days agoChange DetectedThe page now displays a 403 Forbidden error, replacing the study record content. The surrounding header and navigation remain visible, but the main study information is not accessible.SummaryDifference18%

Stay in the know with updates to Nivolumab vs Ipilimumab in Melanoma Recurrence Prevention Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab vs Ipilimumab in Melanoma Recurrence Prevention Clinical Trial page.